Atlantic Healthcare: Addressing the clinical needs of GI patients




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Atlantic Healthcare: Addressing the clinical needs of GI patients
Released on: January 27, 2017. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Atlantic Healthcare plc is an emerging trans-Atlantic pharmaceutical group addressing the clinical needs of patients under specialist care, with an existing focus on gastrointestinal (GI) disease.
  • Summary
  • Participants
  • Company
Atlantic Healthcare plc is an emerging trans-Atlantic pharmaceutical group addressing the clinical needs of patients under specialist care, with an existing focus on gastrointestinal (GI) disease. Adrian Dawkes talks to Toby Wilson Waterworth, CEO about the companies aims to deliver on its commercialisation strategy through in-house product development, out-licensing of assets in non-core territories, and the acquisition of complementary pipeline products.
Toby Wilson Waterworth, CEO
Atlantic Healthcare plc is an emerging trans-Atlantic pharmaceutical group addressing the clinical needs of patients under specialist care, with an existing focus on gastrointestinal (GI) disease. The Group intends to market its products directly in Europe and the U.S., and partner in other markets including Canada and Japan. Atlantic Healthcare has its corporate office near Cambridge, UK and a commercial office in Raleigh, North Carolina, U.S.. The Group has an experienced international Board of Directors and Leadership Team with a deep knowledge of development, regulatory filings and commercialisation of products in the U.S. and European markets. Atlantic Healthcare aims to deliver on its commercialisation strategy through in-house product development, out-licensing of assets in non-core territories, and the acquisition of complementary pipeline products. The Group's lead product, alicaforsen, is progressing through Phase 3 clinical development in pouchitis, a form of inflammatory bowel disease (IBD), and has potential applications in multiple IBD indications. The Group's vision is to establish an industry-leading hospital and specialist-care focussed business that positively transforms patients’ lives.